Jonathan Rigby

Mr. Jonathan M.
Rigby is a Chief Executive Officer at Sernova Biotherapeutics, Inc., a Chairman & Chief Business Officer at BioPlus Acquisition Corp.
and a Chairman at Association of Needle-Free Injection Manufacturers.
He is on the Board of Directors at Oncolytics Biotech, Inc., Aurimi Therapeutics, Inc., Exciting Instruments Ltd., ReAlta Life Sciences, Inc. and Thermalin, Inc. Mr. Rigby was previously employed as a President, Group CEO & Director by Revolo Biotherapeutics Ltd., a Chairman by CollPlant Biotechnologies Ltd., an Independent Non-Executive Director by Xeris Pharmaceuticals, Inc., a President, Chief Executive Officer & Director by SteadyMed Ltd., a President, Chief Executive Officer & Director by SteadyMed Therapeutics, Inc., a Vice President-Business Development by Zogenix, Inc., a Vice President-Business Development by Aradigm Corp., a Head-Business Development & Sales by Profile Therapeutics Plc, and a Principal by Merck & Co., Inc. He received his undergraduate degree from The University of Sheffield and an MBA from the University of Portsmouth.